Gemcitabine
About
Therapy type: Chemotherapy
Therapy strategy: Antimetabolite
Mappings
NCI Thesaurus: Gemcitabine (coding:ncit:C66876)
RxNorm: gemcitabine (coding:rxcui:12574, coding:omop:1314924)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.
Organizations
Biomarkers
Cancer types
Therapies
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| FDA (4) | Wild type ALK, Wild type EGFR | Non-Small Cell Lung Cancer | Carboplatin, Durvalumab, Gemcitabine, Tremelimumab | |
| FDA (4) | Wild type ALK, Wild type EGFR | Non-Small Cell Lung Cancer | Cisplatin, Durvalumab, Gemcitabine, Tremelimumab | |
| FDA (2) | HER2-positive | Invasive Breast Carcinoma | Gemcitabine, Margetuximab | |
| EMA (1) FDA (2) | ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative | Invasive Breast Carcinoma | Carboplatin, Gemcitabine, Pembrolizumab | |
| EMA (1) FDA (2) | Wild type ALK, Wild type EGFR | Non-Small Cell Lung Cancer | Cisplatin, Durvalumab, Gemcitabine | |
| FDA (2) | Wild type ALK, Wild type EGFR | Non-Small Cell Lung Cancer | Cisplatin, Gemcitabine, Nivolumab | |
| EMA (1) | Wild type ALK, Wild type EGFR | Non-Small Cell Lung Cancer | Cisplatin, Gemcitabine, Pembrolizumab | |
| EMA (1) | Wild type ALK, Wild type EGFR | Non-Small Cell Lung Cancer | Carboplatin, Gemcitabine, Pembrolizumab | |
| EMA (1) | PD-L1 >= 1% | Non-Small Cell Lung Cancer | Cisplatin, Gemcitabine, Nivolumab |